ClinicalTrials.gg
Not yet recruitingNCT07632937Updated Jun 8, 2026

A Study to Assess the Efficacy of Public Health Campaigns in Reducing Lead Exposure

An interventional study of Intensive Public Health Campaign and Standard Information Dissemination in Lead Poisoning and Environmental Exposure, sponsored by International Health Strategies LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by International Health Strategies LLC · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This clinical trial aims to evaluate the effectiveness of targeted public health campaigns in reducing lead exposure among adults living in urban communities with known environmental lead hazards. Lead exposure remains a significant public health concern, particularly in older urban neighborhoods with aging infrastructure and legacy contamination. Despite existing regulations and remediation efforts, many communities continue to experience elevated blood lead levels, especially among vulnerable populations.

The study will compare the impact of an intensive, multi-modal public health campaign-featuring community workshops, educational materials, and home intervention resources-against standard municipal information dissemination. By assessing changes in blood lead levels and lead-related knowledge, attitudes, and behaviors over a 12-month period, the trial seeks to determine whether enhanced public health outreach can more effectively reduce lead exposure and promote safer practices. The findings will inform future strategies for community-based environmental health interventions.

Read the detailed description

Lead exposure is a persistent environmental health issue, particularly in urban areas with older housing stock, deteriorating paint, and legacy industrial contamination. Chronic lead exposure, even at low levels, has been associated with neurodevelopmental deficits in children and cardiovascular, renal, and cognitive effects in adults. Despite regulatory progress, disparities in lead exposure persist, often affecting low-income and minority communities.

Traditional public health approaches have relied on passive dissemination of information via municipal websites, pamphlets, and occasional community events. However, evidence suggests that more intensive, community-engaged interventions may be necessary to change behaviors and reduce environmental risks. This study is designed to rigorously assess the efficacy of a comprehensive public health campaign compared to standard information dissemination in reducing lead exposure.

The trial will enroll households from urban neighborhoods identified through environmental surveillance as having elevated lead risks. Eligible participants will be randomized to either the intensive campaign arm or the standard information arm. The intensive campaign will include a series of interactive community workshops, distribution of tailored educational materials, provision of lead-safe cleaning kits, and access to home visits by trained health educators. The control group will receive the standard municipal information package currently in use.

Primary outcomes will include changes in blood lead levels among index participants at baseline and after 12 months. Secondary outcomes will assess changes in lead-related knowledge, adoption of lead-safe practices, and environmental lead measurements in the home. The study will also monitor the incidence of new cases of elevated blood lead and assess participant satisfaction with the interventions.

Data will be collected through home visits, validated questionnaires, and laboratory testing. The trial will use a parallel-group, randomized controlled design with community-level randomization to minimize contamination. Results will inform policymakers and public health practitioners regarding the value of intensive, community-based approaches for environmental hazard reduction.

02

Conditions studied

  • Lead Poisoning
  • Environmental Exposure

Browse trials for

Keywords

  • lead poisoning
  • lead
03

In context

Lead Poisoning

27 studies on the registry are indexed under Lead Poisoning; 2 are open to participants now.

This study's planned enrollment of 400 is above the median of 175 across 11 interventional studies indexed under Lead Poisoning.

Browse Lead Poisoning studies →

Lead sponsor

This is the only study on the registry with International Health Strategies LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident of selected urban neighborhoods with documented environmental lead risk
  • Household includes at least one adult aged 18-75 years willing to participate
  • Willing to provide
  • Willing to allow home visits and blood sampling
  • Able to understand study procedures and interventions

Exclusion criteria

Exclusion Criteria:

  • Planning to relocate from the area within the next 12 months
  • Household member with a known diagnosis of severe anemia or bleeding disorder
  • Participation in another intervention study targeting lead exposure in the past 12 months
  • Inability or unwillingness to comply with study procedures
  • Household with known ongoing lead remediation efforts during the study period
  • Pregnant women (due to additional ethical considerations for blood sampling)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intensive Public Health Campaign

    Participants receive an intensive, multi-modal public health campaign including workshops, educational materials, lead-safe cleaning kits, and home visits by health educators.

    Behavioral: Intensive Public Health Campaign

  • Active comparator
    Standard Information Dissemination

    Participants receive the standard municipal information package on lead exposure prevention currently distributed by city health departments.

    Behavioral: Standard Information Dissemination

Interventions

  • BehavioralIntensive Public Health Campaign

    A comprehensive intervention including: (1) three interactive community workshops on lead risks and prevention, (2) distribution of tailored educational materials, (3) provision of lead-safe cleaning kits (HEPA vacuums, cleaning supplies), and (4) two home visits by trained health educators to reinforce messages and assess household practices. Delivered over a 12-month period.

  • BehavioralStandard Information Dissemination

    Provision of standard municipal information on lead exposure prevention, including pamphlets and website links, as currently distributed by public health authorities. No additional workshops or home visits provided.

06

What researchers measure

Primary outcomes

  1. Change in Blood Lead Level

    Mean change in venous blood lead concentration (μg/dL) among index household participants from baseline to 12 months.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Change in Lead-Related Knowledge

    Change in scores on a validated questionnaire assessing knowledge of lead exposure risks and prevention strategies.

    Time frame: Through study completion, an average of 1 year

  2. Adoption of Lead-Safe Practices

    Proportion of households reporting regular use of lead-safe cleaning and food preparation practices, as assessed by structured survey.

    Time frame: Through study completion, an average of 1 year

  3. Environmental Lead Levels in Home

    Change in environmental lead concentrations (surface dust, tap water) measured in the home.

    Time frame: Through study completion, an average of 1 year

  4. Incidence of New Elevated Blood Lead Cases

    Number of new cases of blood lead ≥5 μg/dL among children and adults during the study period.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • Philadelphia City Center
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Still deciding based on direction of the study.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632937
Lead sponsor
International Health Strategies LLC
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jun 8, 2026

Study contacts

Brian Goldstein, MD MPH
Contact
Brian.Goldstein@intlhealthstrategies.com
215-287-7688
Brian Goldstein, MD MPH
study director · International Health Strategies LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion